» Articles » PMID: 14624166

Twenty-four Hour Ambulatory Blood Pressure Monitoring Pattern of Resistant Hypertension

Overview
Date 2003 Nov 19
PMID 14624166
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Ambulatory blood pressure monitoring (ABPM) is a tool to diagnose resistant hypertension (RH). The objective of this study is to describe the pattern of 24-h ABPM in patients using at least three anti hypertensive drugs without blood pressure (BP) control, classifying them as true RH or white-coat RH.

Methods: A cross-sectional study involving resistant hypertensives that were submitted to clinical, laboratory and 2D-echocardiographic evaluation. Ambulatory blood pressure monitoring was used to diagnose true or white-coat RH. The chi-squared test was used for comparisons among categorical variables and Kruskall-Wallis test for continuous ones.

Results: Of the 286 patients, 161 (56.3%) were classified as true RH and 125 (43.7%) as white-coat RH. Sex, age, office BP and the cardiovascular risk factors for both groups were similar. True resistant hypertensives had more target organ damage then white-coat resistant hypertensives; nephropathy (40.1 versus 23.9%, P=0.007) and left ventricular hypertrophy (83.3 versus 76.3%, P=0.05). In ABPM, the true RH group had a smaller nocturnal systolic and diastolic BP reduction (6.4+/-8.8 versus 9.8+/-7.5 mmHg, P=0.0004; 10.4+/-9.6 versus 13.6+/-9.2 mmHg, P=0.001) and 68.7% of them were non-dippers versus 49.6% in the white-coat RH group (P=0.001). True RH also had a larger 24 h pulse pressure (65.8+/-13.7 versus 51.5+/-10.0 mmHg, P < 0.0001).

Conclusions: Ambulatory blood pressure monitoring is a fundamental tool to diagnose RH, and to check treatment efficacy. The presence of a greater pulse pressure and a lower nocturnal blood pressure reduction in true RH patients may be responsible for this increased cardiovascular risk profile.

Citing Articles

Systolic Blood Pressure and Pulse Pressure Are Predictors of Future Cardiovascular Events in Patients with True Resistant Hypertension.

Mesquita Bastos J, Ferraz L, Pereira F, Lopes S Diagnostics (Basel). 2023; 13(10).

PMID: 37238300 PMC: 10217577. DOI: 10.3390/diagnostics13101817.


Urinary Dickkopf-3 (DKK3) Is Associated with Greater eGFR Loss in Patients with Resistant Hypertension.

Schafer A, Pieper D, Dihazi H, Dihazi G, Luders S, Koziolek M J Clin Med. 2023; 12(3).

PMID: 36769689 PMC: 9918035. DOI: 10.3390/jcm12031034.


Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension.

Schafer A, Kuczera T, Wurm-Kuczera R, Muller D, Born E, Lipphardt M J Clin Hypertens (Greenwich). 2021; 23(7):1363-1371.

PMID: 34101968 PMC: 8678808. DOI: 10.1111/jch.14302.


Translating research evidence into clinical practice: a reminder of important clinical lessons in management of resistant hypertension through a case study in general practice.

Yap T, Affandi J, Reid C, Xu D BMJ Case Rep. 2020; 13(6).

PMID: 32606122 PMC: 7328755. DOI: 10.1136/bcr-2020-235007.


Brazilian Position Statement on Resistant Hypertension - 2020.

Yugar-Toledo J, Junior H, Gus M, Rosito G, Scala L, Muxfeldt E Arq Bras Cardiol. 2020; 114(3):576-596.

PMID: 32267335 PMC: 7792719. DOI: 10.36660/abc.20200198.